{"denoms":[{"counts":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"80"}],"units":"Participants"}],"groups":[{"description":"Patients receive temsirolimus IV over 30-60 minutes and cetuximab IV over 1-2 hours once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.","id":"BG000","title":"Arm A (Cetuximab and Temsirolimus)"},{"description":"Patients receive temsirolimus as in Arm A. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may cross over to Arm A.","id":"BG001","title":"Arm B (Temsirolimus)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"48","upperLimit":"86","value":"63"},{"groupId":"BG001","lowerLimit":"39","upperLimit":"81","value":"63"},{"groupId":"BG002","lowerLimit":"39","upperLimit":"86","value":"63"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"11"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"69"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"80"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"Three patients from each treatment arm did not start treatment and are considered non-evaluable."}